Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway - PubMed (original) (raw)
. 1997 Apr 15;11(8):957-72.
doi: 10.1101/gad.11.8.957.
Affiliations
- PMID: 9136925
- DOI: 10.1101/gad.11.8.957
Free article
Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
J A Diehl et al. Genes Dev. 1997.
Free article
Abstract
The expression of D-type G1 cyclins and their assembly with their catalytic partners, the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), into active holoenzyme complexes are regulated by growth factor-induced signals. In turn, the ability of cyclin D-dependent kinases to trigger phosphorylation of the retinoblastoma (Rb) protein in the mid- to late G1 phase of the cell cycle makes the inactivation of Rb's growth suppressive function a mitogen-dependent step. The ability of D-type cyclins to act as growth factor sensors depends not only on their rapid induction by mitogens but also on their inherent instability, which ensures their precipitous degradation in cells deprived of growth factors. However, the mechanisms governing the turnover of D-type cyclins have not yet been elucidated. We now show that cyclin D1 turnover is governed by ubiquitination and proteasomal degradation, which are positively regulated by cyclin D1 phosphorylation on threonine-286. Although "free" or CDK4-bound cyclin D1 molecules are intrinsically unstable (t1/2 < 30 min), a cyclin D1 mutant (T286A) containing an alanine for threonine-286 substitution fails to undergo efficient polyubiquitination in an in vitro system or in vivo, and it is markedly stabilized (t1/2 approximately 3.5 hr) when inducibly expressed in either quiescent or proliferating mouse fibroblasts. Phosphorylation of cyclin D1 on threonine-286 also occurs in insect Sf9 cells, and although the process is enhanced significantly by the binding of cyclin D1 to CDK4, it does not depend on CDK4 catalytic activity. This implies that another kinase can phosphorylate cyclin D1 to accelerate its destruction and points to yet another means by which cyclin D-dependent kinase activity may be exogenously regulated.
Similar articles
- Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Lukas J, et al. Mol Cell Biol. 1995 May;15(5):2600-11. doi: 10.1128/MCB.15.5.2600. Mol Cell Biol. 1995. PMID: 7739541 Free PMC article. - Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.
Diehl JA, Cheng M, Roussel MF, Sherr CJ. Diehl JA, et al. Genes Dev. 1998 Nov 15;12(22):3499-511. doi: 10.1101/gad.12.22.3499. Genes Dev. 1998. PMID: 9832503 Free PMC article. - Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM, Dickson RB. Benaud CM, et al. Oncogene. 2001 Jul 27;20(33):4554-67. doi: 10.1038/sj.onc.1204609. Oncogene. 2001. PMID: 11494151 - Cyclin proteolysis as a retinoid cancer prevention mechanism.
Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E. Dragnev KH, et al. Ann N Y Acad Sci. 2001 Dec;952:13-22. doi: 10.1111/j.1749-6632.2001.tb02724.x. Ann N Y Acad Sci. 2001. PMID: 11795432 Review. - Cycling to cancer with cyclin D1.
Diehl JA. Diehl JA. Cancer Biol Ther. 2002 May-Jun;1(3):226-31. doi: 10.4161/cbt.72. Cancer Biol Ther. 2002. PMID: 12432268 Review.
Cited by
- Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing.
Sharma A, Liu X, Chandra V, Rai R, Benbrook DM, Woo S. Sharma A, et al. AAPS J. 2023 Dec 12;26(1):5. doi: 10.1208/s12248-023-00874-7. AAPS J. 2023. PMID: 38087107 - Multiple cullin-associated E3 ligases regulate cyclin D1 protein stability.
Lu K, Zhang M, Wei G, Xiao G, Tong L, Chen D. Lu K, et al. Elife. 2023 Nov 9;12:e80327. doi: 10.7554/eLife.80327. Elife. 2023. PMID: 37943017 Free PMC article. - Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics.
Pustelny K, Grygier P, Barzowska A, Pucelik B, Matsuda A, Mrowiec K, Slugocka E, Popowicz GM, Dubin G, Czarna A. Pustelny K, et al. Sci Rep. 2023 Oct 23;13(1):18114. doi: 10.1038/s41598-023-44810-3. Sci Rep. 2023. PMID: 37872245 Free PMC article. - RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity.
Morinaka T, Sakai N, Takayashiki T, Kuboki S, Takano S, Ohira G, Matsubara H, Ohtsuka M. Morinaka T, et al. Int J Oncol. 2023 Nov;63(5):120. doi: 10.3892/ijo.2023.5568. Epub 2023 Sep 1. Int J Oncol. 2023. PMID: 37654197 Free PMC article. - Regulation of TRIB1 abundance in hepatocyte models in response to proteasome inhibition.
Soubeyrand S, Lau P, McPherson R. Soubeyrand S, et al. Sci Rep. 2023 Jun 8;13(1):9320. doi: 10.1038/s41598-023-36512-7. Sci Rep. 2023. PMID: 37291259 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials